Previous close | 518.36 |
Open | 519.39 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 524.52 - 531.72 |
52-week range | 446.52 - 557.99 |
Volume | |
Avg. volume | 59,318 |
Market cap | N/A |
Beta (5Y monthly) | 0.60 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 11 Oct 2024 - 15 Oct 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Earnings for healthcare companies have declined for six straight quarters. But analysts have a more positive outlook going into second quarter earnings.
GoodRx announced a new partnership with Boehringer Ingelheim to provide discounts for a biosimilar to rheumatoid arthritis drug Humira Thursday, adding to an increasingly competitive market.